CSL agrees Alentis drug deal as CSL stock has AUD 89.7 billion value

Published on 10/15/2026 at 10:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The deal covers up to USD 1.2 billion in milestones for rare diseases. CSL stock costs EUR 115.35 on October 15, 2026.

Deal terms and upcoming dates

CSL and Alentis announced their global collaboration on October 5, 2026, including USD 355 million upfront and up to USD 1.2 billion in milestones.
CSL reported USD 15.8 billion in fiscal year 2026 revenue, down 1 percent in constant currency.
CSL stock trades at EUR 115.35 at 10:39 a.m. CEST at Lang & Schwarz on October 15, 2026.
CSL's annual general meeting is scheduled for October 27, 2026.

CSL, AU000000CSL8, Illustration mit AI erstellt.

CSL Limited (ISIN AU000000CSL8) has a market value of AUD 89.7 billion as the biotechnology group advances a rare-disease partnership with Alentis. The agreement announced on October 5, 2026 covers lixudebart, an investigational treatment for kidney and liver diseases, according to CSL.

Deal terms reach USD 1.2 billion

CSL will pay Alentis USD 355 million upfront and fund the ongoing Phase 2 RENAL trial, a planned Phase 3 trial and additional studies. Alentis can receive up to USD 1.2 billion in commercial milestones, while global profits would be shared 55 percent with CSL and 45 percent with Alentis, Reuters reported on October 5, 2026.

The clinical asset is being tested in AAV-RPGN, a severe autoimmune kidney disease, and is also planned for focal segmental glomerulosclerosis and primary sclerosing cholangitis. An interim analysis covered 26 patients in the Phase 2 RENAL trial, giving the transaction a clinical base but not an approved product.

What does fiscal year 2026 show?

CSL's fiscal year 2026 revenue reached USD 15.8 billion, down 1 percent in constant currency, while underlying NPATA fell 2 percent to USD 3.1 billion. Restructuring costs and impairments produced a statutory loss of USD 2.6 billion, although operating cash flow reached USD 3.5 billion, according to The Motley Fool Australia. The comparison points to a business with cash generation alongside heavy accounting charges.

Dates and market value

CSL's annual general meeting is scheduled for October 27, 2026. The next earnings date is listed as February 10, 2027, according to Simply Wall St. On the ASX, CSL was last at AUD 186.90 on October 15, 2026 at 3:10 p.m. AEDT, while the 52-week range stood at AUD 90.00 to AUD 222.47.

CSL stock trades at EUR 115.35

CSL stock was trading at EUR 115.35 at Lang & Schwarz on October 15, 2026 at 10:39 a.m. CEST. The Australian listing was last at AUD 186.90 on the same date, separately from the euro quote. The further course of trading is shown by the continuously updated real-time quote of CSL stock.